Current reports
6-K
Report of Foreign Private Issuer
15 Apr 24
6-K
IceCure Medical Reports Final ICE3 Breast Cancer
15 Apr 24
6-K
Report of Foreign Private Issuer
3 Apr 24
6-K
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
2 Apr 24
6-K
Report of Foreign Private Issuer
19 Mar 24
6-K
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
12 Mar 24
6-K
Report of Foreign Private Issuer
4 Mar 24
6-K
Study Using IceCure’s ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
26 Feb 24
6-K
IceCure to submit full 5-year dataset from entire ICE3 study population to the FDA this spring, ahead of previous expectation
30 Jan 24
6-K
Report of Foreign Private Issuer
12 Jan 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
12 Jan 24
S-8
Registration of securities for employees
30 Mar 23
424B5
Prospectus supplement for primary offering
22 Dec 22
424B5
Prospectus supplement for primary offering
20 Dec 22
POS AM
Prospectus update (post-effective amendment)
22 Sep 22
F-3
Shelf registration (foreign)
2 Sep 22
POS AM
Prospectus update (post-effective amendment)
3 Jun 22
S-8
Registration of securities for employees
29 Apr 22
POS AM
Prospectus update (post-effective amendment)
4 Apr 22
POS AM
Prospectus update (post-effective amendment)
1 Apr 22
Proxies
No filings
Other
CORRESP
Correspondence with SEC
10 Jan 24
UPLOAD
Letter from SEC
10 Jan 24
UPLOAD
Letter from SEC
9 Jan 24
CORRESP
Correspondence with SEC
13 Oct 23
EFFECT
Notice of effectiveness
26 Sep 22
EFFECT
Notice of effectiveness
15 Sep 22
CORRESP
Correspondence with SEC
12 Sep 22
UPLOAD
Letter from SEC
7 Sep 22
EFFECT
Notice of effectiveness
9 Jun 22
EFFECT
Notice of effectiveness
5 Apr 22